JP2019047818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019047818A5 JP2019047818A5 JP2018233311A JP2018233311A JP2019047818A5 JP 2019047818 A5 JP2019047818 A5 JP 2019047818A5 JP 2018233311 A JP2018233311 A JP 2018233311A JP 2018233311 A JP2018233311 A JP 2018233311A JP 2019047818 A5 JP2019047818 A5 JP 2019047818A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- sirpα
- gene
- human
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283984 Rodentia Species 0.000 claims 62
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 56
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 26
- 210000004027 cell Anatomy 0.000 claims 25
- 108700024394 Exon Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 229940000406 drug candidate Drugs 0.000 claims 3
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881261P | 2013-09-23 | 2013-09-23 | |
| US61/881,261 | 2013-09-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544055A Division JP6453893B2 (ja) | 2013-09-23 | 2014-09-23 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020026122A Division JP6875573B2 (ja) | 2013-09-23 | 2020-02-19 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019047818A JP2019047818A (ja) | 2019-03-28 |
| JP2019047818A5 true JP2019047818A5 (enExample) | 2020-02-27 |
| JP6665269B2 JP6665269B2 (ja) | 2020-03-13 |
Family
ID=51663510
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544055A Active JP6453893B2 (ja) | 2013-09-23 | 2014-09-23 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2018233311A Active JP6665269B2 (ja) | 2013-09-23 | 2018-12-13 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2020026122A Active JP6875573B2 (ja) | 2013-09-23 | 2020-02-19 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2021072857A Active JP7149370B2 (ja) | 2013-09-23 | 2021-04-22 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544055A Active JP6453893B2 (ja) | 2013-09-23 | 2014-09-23 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020026122A Active JP6875573B2 (ja) | 2013-09-23 | 2020-02-19 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
| JP2021072857A Active JP7149370B2 (ja) | 2013-09-23 | 2021-04-22 | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US9193977B2 (enExample) |
| EP (5) | EP3175706B1 (enExample) |
| JP (4) | JP6453893B2 (enExample) |
| KR (2) | KR102370419B1 (enExample) |
| CN (2) | CN108441497B (enExample) |
| AU (3) | AU2014321187B2 (enExample) |
| CA (1) | CA2925564C (enExample) |
| CY (1) | CY1121410T1 (enExample) |
| DK (4) | DK3434101T5 (enExample) |
| ES (4) | ES3037239T3 (enExample) |
| FI (2) | FI3434101T3 (enExample) |
| HR (3) | HRP20231121T1 (enExample) |
| HU (3) | HUE042412T2 (enExample) |
| IL (4) | IL297607B2 (enExample) |
| LT (3) | LT3175706T (enExample) |
| MX (1) | MX368931B (enExample) |
| NZ (1) | NZ717817A (enExample) |
| PH (1) | PH12016500342A1 (enExample) |
| PL (3) | PL4269430T3 (enExample) |
| PT (4) | PT3175706T (enExample) |
| RS (3) | RS67091B1 (enExample) |
| RU (2) | RU2671166C2 (enExample) |
| SG (3) | SG11201601184UA (enExample) |
| SI (3) | SI3175706T1 (enExample) |
| SM (3) | SMT202500280T1 (enExample) |
| TR (1) | TR201901782T4 (enExample) |
| WO (1) | WO2015042557A1 (enExample) |
| ZA (1) | ZA201601138B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| KR102241962B1 (ko) | 2012-09-07 | 2021-04-20 | 예일 유니버시티 | 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법 |
| DK4389764T3 (da) | 2012-11-05 | 2026-04-13 | Regeneron Pharma | Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf |
| HRP20231121T1 (hr) | 2013-09-23 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale |
| JP6492095B2 (ja) | 2013-10-15 | 2019-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒト化ｉｌ−１５動物 |
| MY183188A (en) | 2013-11-19 | 2021-02-18 | Regeneron Pharma | Non-human animals having a humanized b-cell activating factor gene |
| RS60398B1 (sr) | 2014-04-08 | 2020-07-31 | Regeneron Pharma | Ne-humane životinje sa humanizovanim fc-gama receptorima |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| EP3482629B1 (en) | 2014-05-19 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals expressing human epo |
| WO2015196051A1 (en) | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| BR112017010793A2 (pt) | 2014-11-24 | 2017-12-26 | Regeneron Pharma | animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo. |
| BR112017010490A2 (pt) | 2014-12-05 | 2018-04-03 | Regeneron Pharma | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. |
| ES2841353T3 (es) | 2014-12-09 | 2021-07-08 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado |
| ES2950399T3 (es) * | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos |
| CN104904661B (zh) * | 2015-06-05 | 2018-07-24 | 杭州正因生物技术有限公司 | 一种人源化小鼠 |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| CN108366548B (zh) | 2015-11-20 | 2021-10-08 | 瑞泽恩制药公司 | 具有人源化淋巴细胞活化基因3的非人动物 |
| WO2017136712A1 (en) | 2016-02-04 | 2017-08-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered angptl8 gene |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| CN108467873B (zh) | 2017-03-17 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
| WO2018177441A1 (en) | 2017-03-31 | 2018-10-04 | Beijing Biocytogen Co., Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα |
| CN108588126B (zh) | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Cd47基因人源化改造动物模型的制备方法及应用 |
| WO2018233608A1 (en) * | 2017-06-19 | 2018-12-27 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric cd28 |
| CN109136261B (zh) | 2017-06-19 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化cd28基因改造动物模型的制备方法及应用 |
| CN111182790A (zh) | 2017-07-31 | 2020-05-19 | 瑞泽恩制药公司 | Crispr报告体非人类动物及其用途 |
| KR102712142B1 (ko) | 2017-07-31 | 2024-10-07 | 리제너론 파마슈티칼스 인코포레이티드 | Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도 |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| EP3592140A1 (en) | 2018-03-19 | 2020-01-15 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
| IL277355B2 (en) | 2018-03-26 | 2025-01-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| MX2020013068A (es) | 2018-07-10 | 2021-03-02 | Univ Kobe Nat Univ Corp | Anticuerpo anti proteína reguladora de señales alfa sirpalfana. |
| CA3098040A1 (en) | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
| US12653168B2 (en) | 2018-09-13 | 2026-06-16 | Regeneron Pharmaceuticals, Inc. | Complement factor H gene knockout rat as a model of C3 glomerulopathy |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020160285A1 (en) * | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION |
| JP7506686B2 (ja) | 2019-04-04 | 2024-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化凝固因子１２遺伝子座を含む非ヒト動物 |
| CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| CN113939595A (zh) | 2019-06-07 | 2022-01-14 | 瑞泽恩制药公司 | 包括人源化白蛋白基因座的非人动物 |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| CN113122574A (zh) * | 2019-12-31 | 2021-07-16 | 百奥赛图(北京)医药科技股份有限公司 | 一种免疫缺陷型人源化非人动物的构建方法 |
| WO2021154791A1 (en) | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| KR20230004472A (ko) | 2020-04-21 | 2023-01-06 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 cxcl13 유전자를 갖는 비인간 동물 |
| JP2024500153A (ja) * | 2020-12-21 | 2024-01-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｓｌｐ遺伝子、ヒト化ｔｓｌｐ受容体遺伝子、及び／又はヒト化ｉｌ７ｒａ遺伝子を有する非ヒト動物 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| AU2022408167A1 (en) | 2021-12-08 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
| US20250143272A1 (en) * | 2022-01-25 | 2025-05-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric nkp46 |
| US20240102045A1 (en) | 2022-07-19 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| EP4593590A1 (en) | 2022-09-29 | 2025-08-06 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| JP2026522329A (ja) | 2023-06-16 | 2026-07-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ベクター、遺伝子改変細胞、およびそれらを含む遺伝子改変非ヒト動物 |
| WO2025171307A1 (en) | 2024-02-08 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2025250495A1 (en) | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
| WO2026096736A1 (en) | 2024-10-31 | 2026-05-07 | Regeneron Pharmaceuticals, Inc. | Rodents expressing humanized polymeric immunoglobulin receptor |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149635A (en) * | 1986-09-12 | 1992-09-22 | Abbott Biotech, Inc. | Messenger RNA stabilization in animal cells |
| PL339463A1 (en) * | 1997-09-12 | 2000-12-18 | Biogen | April - novel protein of growth promoting action |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ATE510020T1 (de) * | 2003-12-24 | 2011-06-15 | G2 Inflammation Pty Ltd | Transgenes nichtmenschliches säugetier mit einem polynukleotid, das für human-c5ar oder humanisiertes c5ar codiert |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| US20060272038A1 (en) * | 2005-05-27 | 2006-11-30 | Michael De Vivo | Transgenic Alzheimer's mouse model vectors and uses thereof |
| US20070028316A1 (en) * | 2005-06-02 | 2007-02-01 | Xiaoxia Li | Transgenic non-human Act1-deficient mammals and uses thereof |
| JP2011500005A (ja) * | 2007-10-11 | 2011-01-06 | ユニバーシティー ヘルス ネットワーク | ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物 |
| EP2262898B1 (en) | 2008-03-07 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| WO2012040207A2 (en) * | 2010-09-20 | 2012-03-29 | Yale University | HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE |
| EP2675901B1 (en) * | 2011-02-14 | 2018-05-30 | Revivicor, Inc. | Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof |
| PT4233537T (pt) * | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| RS63220B1 (sr) | 2011-10-28 | 2022-06-30 | Regeneron Pharma | Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc) |
| SI2818478T1 (sl) | 2011-10-28 | 2017-07-31 | Regeneron Pharmaceuticals, Inc. | Humanizirani il-6 in receptor il-6 |
| KR102295746B1 (ko) | 2011-10-28 | 2021-09-01 | 리제너론 파아마슈티컬스, 인크. | 유전자 변형된 주요 조직적합성 복합체 마우스 |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| KR102241962B1 (ko) | 2012-09-07 | 2021-04-20 | 예일 유니버시티 | 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법 |
| DK4389764T3 (da) | 2012-11-05 | 2026-04-13 | Regeneron Pharma | Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf |
| US9848587B2 (en) | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| HRP20231121T1 (hr) | 2013-09-23 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale |
| US20180295818A1 (en) * | 2015-04-30 | 2018-10-18 | Institute Of Immunology Co., Ltd. | TRANSGENIC NON-HUMAN ANIMAL EXPRESSING HUMAN SPECIFIC MOLECULE AND HUMAN FCy RECEPTOR FAMILY |
-
2014
- 2014-09-23 HR HRP20231121TT patent/HRP20231121T1/hr unknown
- 2014-09-23 SG SG11201601184UA patent/SG11201601184UA/en unknown
- 2014-09-23 CN CN201810267662.3A patent/CN108441497B/zh active Active
- 2014-09-23 DK DK18192264.2T patent/DK3434101T5/da active
- 2014-09-23 ES ES23185050T patent/ES3037239T3/es active Active
- 2014-09-23 RS RS20250788A patent/RS67091B1/sr unknown
- 2014-09-23 LT LTEP16206491.9T patent/LT3175706T/lt unknown
- 2014-09-23 SI SI201431078T patent/SI3175706T1/sl unknown
- 2014-09-23 NZ NZ717817A patent/NZ717817A/en unknown
- 2014-09-23 PL PL23185050.4T patent/PL4269430T3/pl unknown
- 2014-09-23 PT PT16206491T patent/PT3175706T/pt unknown
- 2014-09-23 US US14/493,745 patent/US9193977B2/en active Active
- 2014-09-23 AU AU2014321187A patent/AU2014321187B2/en active Active
- 2014-09-23 PL PL18192264.2T patent/PL3434101T3/pl unknown
- 2014-09-23 EP EP16206491.9A patent/EP3175706B1/en active Active
- 2014-09-23 HU HUE16206491A patent/HUE042412T2/hu unknown
- 2014-09-23 EP EP14781783.7A patent/EP2922394B1/en active Active
- 2014-09-23 WO PCT/US2014/056910 patent/WO2015042557A1/en not_active Ceased
- 2014-09-23 HU HUE23185050A patent/HUE072332T2/hu unknown
- 2014-09-23 FI FIEP18192264.2T patent/FI3434101T3/fi active
- 2014-09-23 LT LTEP23185050.4T patent/LT4269430T/lt unknown
- 2014-09-23 DK DK14781783.7T patent/DK2922394T3/en active
- 2014-09-23 EP EP18192264.2A patent/EP3434101B1/en active Active
- 2014-09-23 IL IL297607A patent/IL297607B2/en unknown
- 2014-09-23 DK DK16206491.9T patent/DK3175706T3/en active
- 2014-09-23 FI FIEP23185050.4T patent/FI4269430T3/fi active
- 2014-09-23 TR TR2019/01782T patent/TR201901782T4/tr unknown
- 2014-09-23 SI SI201432112T patent/SI4269430T1/sl unknown
- 2014-09-23 RS RS20230816A patent/RS64573B1/sr unknown
- 2014-09-23 SM SM20250280T patent/SMT202500280T1/it unknown
- 2014-09-23 KR KR1020167008334A patent/KR102370419B1/ko active Active
- 2014-09-23 EP EP23185050.4A patent/EP4269430B1/en active Active
- 2014-09-23 ES ES18192264T patent/ES2959333T3/es active Active
- 2014-09-23 CN CN201480051997.1A patent/CN105592695B/zh active Active
- 2014-09-23 HU HUE18192264A patent/HUE063376T2/hu unknown
- 2014-09-23 PL PL16206491T patent/PL3175706T3/pl unknown
- 2014-09-23 CA CA2925564A patent/CA2925564C/en active Active
- 2014-09-23 RU RU2016110462A patent/RU2671166C2/ru active
- 2014-09-23 PT PT147817837T patent/PT2922394T/pt unknown
- 2014-09-23 DK DK23185050.4T patent/DK4269430T3/da active
- 2014-09-23 SM SM20190067T patent/SMT201900067T1/it unknown
- 2014-09-23 RU RU2018136614A patent/RU2018136614A/ru not_active Application Discontinuation
- 2014-09-23 JP JP2016544055A patent/JP6453893B2/ja active Active
- 2014-09-23 SG SG10201801326PA patent/SG10201801326PA/en unknown
- 2014-09-23 MX MX2016003636A patent/MX368931B/es active IP Right Grant
- 2014-09-23 SG SG10201902547SA patent/SG10201902547SA/en unknown
- 2014-09-23 ES ES16206491T patent/ES2710282T3/es active Active
- 2014-09-23 SM SM20230287T patent/SMT202300287T1/it unknown
- 2014-09-23 RS RS20190162A patent/RS58365B1/sr unknown
- 2014-09-23 LT LTEP18192264.2T patent/LT3434101T/lt unknown
- 2014-09-23 KR KR1020227006825A patent/KR102407354B1/ko active Active
- 2014-09-23 SI SI201432041T patent/SI3434101T1/sl unknown
- 2014-09-23 ES ES14781783.7T patent/ES2624614T3/es active Active
- 2014-09-23 PT PT231850504T patent/PT4269430T/pt unknown
- 2014-09-23 EP EP25183430.5A patent/EP4635977A3/en active Pending
- 2014-09-23 HR HRP20251062TT patent/HRP20251062T1/hr unknown
- 2014-09-23 PT PT181922642T patent/PT3434101T/pt unknown
- 2014-10-17 US US14/516,606 patent/US9127292B2/en active Active
-
2015
- 2015-10-14 US US14/882,531 patent/US9462794B2/en active Active
-
2016
- 2016-02-18 ZA ZA2016/01138A patent/ZA201601138B/en unknown
- 2016-02-18 IL IL244187A patent/IL244187B/en active IP Right Grant
- 2016-02-19 PH PH12016500342A patent/PH12016500342A1/en unknown
- 2016-09-13 US US15/263,916 patent/US9700027B2/en active Active
-
2017
- 2017-06-06 US US15/615,298 patent/US9901083B2/en active Active
-
2018
- 2018-01-10 US US15/866,632 patent/US10206379B2/en active Active
- 2018-11-12 IL IL262958A patent/IL262958A/en active IP Right Grant
- 2018-12-13 JP JP2018233311A patent/JP6665269B2/ja active Active
-
2019
- 2019-01-03 US US16/238,589 patent/US10426146B2/en active Active
- 2019-02-05 HR HRP20190227TT patent/HRP20190227T1/hr unknown
- 2019-02-07 CY CY20191100163T patent/CY1121410T1/el unknown
- 2019-08-15 US US16/541,334 patent/US11019810B2/en active Active
-
2020
- 2020-02-19 JP JP2020026122A patent/JP6875573B2/ja active Active
- 2020-11-12 IL IL278679A patent/IL278679B2/en unknown
- 2020-12-08 AU AU2020286187A patent/AU2020286187B2/en active Active
-
2021
- 2021-04-22 JP JP2021072857A patent/JP7149370B2/ja active Active
- 2021-04-27 US US17/241,171 patent/US12161097B2/en active Active
-
2024
- 2024-09-02 AU AU2024216527A patent/AU2024216527A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krusche et al. | Desmoglein 2 mutant mice develop cardiac fibrosis and dilation | |
| Banerjee et al. | Targeted ablation of nesprin 1 and nesprin 2 from murine myocardium results in cardiomyopathy, altered nuclear morphology and inhibition of the biomechanical gene response | |
| Guo et al. | Keratin 14-dependent disulfides regulate epidermal homeostasis and barrier function via 14-3-3σ and YAP1 | |
| WO2015042557A4 (en) | Non-human animals having a humanized signal-regulatory protein gene | |
| JP2019022518A5 (enExample) | ||
| JP2018500012A5 (enExample) | ||
| Kim et al. | S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model | |
| JP2017514501A5 (enExample) | ||
| CN113940309B (zh) | 一种慢性萎缩性胃炎病变的模拟方法及小鼠造模鉴定方法 | |
| Leclère et al. | Otoferlin as a multirole Ca2+ signaling protein: from inner ear synapses to cancer pathways | |
| JP2017500854A (ja) | ポリペプチド、核酸およびその使用 | |
| Du et al. | A point mutation (R192H) in the C-terminus of human cardiac troponin I causes diastolic dysfunction in transgenic mice | |
| Wang et al. | Translocator protein (Tspo) gene promoter-driven green fluorescent protein synthesis in transgenic mice: an in vivo model to study Tspo transcription | |
| JP2019506897A5 (enExample) | ||
| JPWO2002039813A1 (ja) | Ｐｄ−１欠損マウスおよびその用途 | |
| JP5756014B2 (ja) | がんの診断および治療のためのｖｈｚ | |
| EP3484501A1 (en) | Methods of diagnosis and treatment of pre-eclampsia | |
| Sanematsu et al. | Fhod1, an actin‐organizing formin family protein, is dispensable for cardiac development and function in mice | |
| CN106994185A (zh) | Tie2对视网膜及其他组织中静脉血管的保护作用及应用 | |
| Zupkovitz et al. | Phylogenetic analysis and expression profiling of the Klotho gene family in the short-lived African killifish Nothobranchius furzeri | |
| CN113817769B (zh) | 射血分数保留的心衰动物模型的构建方法及应用 | |
| CA2438219A1 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale reversion tumorale apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
| JP2023543232A (ja) | ヘッジホッグシグナル伝達経路の活性化のための強力な結合剤 | |
| JP2002504806A (ja) | 糖尿病媒介タンパク質およびその治療的使用 | |
| JP5971966B2 (ja) | Ｔｄｐ−４３の凝集体が蓄積する疾患の発症リスクを予測する方法、診断薬及び治療薬 |